Analyst Activity – BMO Capital Markets Reiterates Buy on Merck & Co. (NYSE:MRK)

24

Analyst Ratings For Merck & Co. (NYSE:MRK)

Today, BMO Capital Markets reiterated its Buy rating on Merck & Co. (NYSE:MRK) with a price target of $70.00.

There are 1 sell rating, 6 hold ratings, 11 buy ratings on the stock.

The current consensus rating on Merck & Co. (NYSE:MRK) is Buy (Score: 2.56) with a consensus target price of $67.67 per share, a potential 5.55% upside.

Some recent analyst ratings include

  • 3/21/2017-BMO Capital Markets Reiterated Rating of Buy.
  • 3/20/2017-Leerink Swann Reiterated Rating of Market Perform.
  • 3/11/2017-Jefferies Group LLC Reiterated Rating of Underperform.
  • 2/24/2017-Sanford C. Bernstein Reiterated Rating of Market Perform.
  • 1/13/2017-Bryan, Garnier & Co initiated coverage with a Buy rating.
  • 1/12/2017-Piper Jaffray Companies Upgrade from a “Neutral ” rating to a ” Overweight” rating.
  • 1/12/2017-Morgan Stanley Upgrade from a “Equal Weight ” rating to a ” Overweight” rating.

Dividend information for Merck & Co. (NYSE:MRK)

Merck & Co. (NYSE:MRK) pays an annual dividend of $1.88 with a yield of 2.93% and an average dividend growth of 2.30% based on a 3 Year Average..

Dividend History for Merck & Co. (NYSE:MRK)

  • On 2/28/2017 Merck & Co. announced a quarterly dividend of $0.47 with an ex dividend date of 3/13/2017 which will be payable on 4/7/2017.
  • On 11/22/2016 Merck & Co. announced a quarterly dividend of $0.47 3.05% with an ex dividend date of 12/13/2016 which will be payable on 1/9/2017.
  • On 7/26/2016 Merck & Co. announced a quarterly dividend of $0.46 3.14% with an ex dividend date of 9/13/2016 which will be payable on 10/7/2016.
  • On 5/24/2016 Merck & Co. announced a quarterly dividend of $0.46 3.25% with an ex dividend date of 6/13/2016 which will be payable on 7/8/2016.
  • On 2/23/2016 Merck & Co. announced a quarterly dividend of $0.46 3.64% with an ex dividend date of 3/11/2016 which will be payable on 4/7/2016.
  • On 11/24/2015 Merck & Co. announced a quarterly dividend of $0.46 3.43% with an ex dividend date of 12/11/2015 which will be payable on 1/8/2016.
  • On 7/22/2015 Merck & Co. announced a quarterly dividend of $0.45 3.1% with an ex dividend date of 9/11/2015 which will be payable on 10/7/2015.

Recent Insider Trading Activity For Merck & Co. (NYSE:MRK)
Merck & Co. (NYSE:MRK) has insider ownership of 0.05% and institutional ownership of 74.10%.

  • On 2/8/2017 Patricia F Russo, Director, sold 5,000 with an average share price of $64.42 per share and the total transaction amounting to $322,100.00. View SEC Filing
  • On 2/6/2017 Wendell P Weeks, Director, sold 5,000 with an average share price of $64.51 per share and the total transaction amounting to $322,550.00. View SEC Filing
  • On 2/3/2017 Michael J Holston, EVP, sold 91,959 with an average share price of $63.96 per share and the total transaction amounting to $5,881,697.64. View SEC Filing
  • On 2/3/2017 Thomas R Cech, Director, sold 5,000 with an average share price of $63.42 per share and the total transaction amounting to $317,100.00. View SEC Filing
  • On 11/10/2016 Kenneth C Frazier, Chairman, sold 140,000 with an average share price of $65.03 per share and the total transaction amounting to $9,104,200.00. View SEC Filing
  • On 11/7/2016 Julie L Gerberding, EVP, sold 85,523 with an average share price of $60.02 per share and the total transaction amounting to $5,133,090.46. View SEC Filing
  • On 11/2/2016 Rochelle B Lazarus, Director, sold 20,000 with an average share price of $59.06 per share and the total transaction amounting to $1,181,200.00. View SEC Filing

About Merck & Co. (NYSE:MRK)
Merck & Co., Inc. is a global healthcare company. The Company offers health solutions through its prescription medicines, vaccines, biologic therapies and animal health products, which it markets directly and through its joint ventures. It operates through one segment, Pharmaceutical. The Company’s Pharmaceutical segment includes human health pharmaceutical and vaccine products marketed either directly by the Company or through joint ventures. Human health pharmaceutical products consist of therapeutic and preventive agents, generally sold by prescription, for the treatment of human disorders. The Company sells these human health pharmaceutical products primarily to drug wholesalers and retailers, hospitals, government agencies and managed healthcare providers. The Animal Health segment discovers, develops, manufactures and markets animal health products, including vaccines. The Company’s animal health products are sold to veterinarians, distributors and animal producers.

Recent Trading Activity for Merck & Co. (NYSE:MRK)
Shares of Merck & Co. closed the previous trading session at 64.11 up +0.21 0.33% with 12,971,169 shares trading hands.

An ad to help with our costs